Biotechnological agents for patients with tumor necrosis factor receptor associated periodic syndrome - Therapeutic outcome and predictors of response: real-life data from the AIDA Network

Elena Verrecchia, Donato Rigante, Ludovico Luca Sicignano, Raffaele Manna, Antonio Vitale, Laura Obici, Marco Cattalini, Giuseppe Lopalco, Giampaolo Merlini, Nicola Ricco, Alessandra Soriano, Francesco La Torre, Antonella Insalaco, Lorenzo Dagna, Masen Abdel Jaber, Davide Montin, Giacomo Emmi, Luisa Ciarcia, Sara Barneschi, Paola ParronchiPiero Ruscitti, Maria Cristina Maggio, Ombretta Viapiana, Jurgen Sota, Carla Gaggiano, Roberto Giacomelli, Alessandra Renieri, Caterina Lo Rizzo, Bruno Frediani, Luca Cantarini

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Objective: To describe the role of biotechnological therapies in patients with tumor necrosis factor receptor-associated periodic syndrome (TRAPS) and to identify any predictor of complete response. Methods: Clinical, laboratory and therapeutic data from 44 Caucasian TRAPS patients treated with biologic agents were retrospectively collected in 16 Italian tertiary Centers. Results: A total of 55 biological courses with anakinra (n=26), canakinumab (n=16), anti-TNF-α agents (n=10) and tocilizumab (n=3) were analysed. A complete response was observed in 41 (74.5%) cases, a partial response in 9 (16.4%) cases and a treatment failure in 5 (9.1%) cases. The frequency of TRAPS exacerbations was 458.2 flare/100 patients-year during the 12 months prior to the start of biologic treatment and 65.7 flare/100 patients-years during the first 12 months of therapy (p<0.0001). The median duration of attacks was 5.00 (IQR=10.50) days at the start of biologics and 1.00 (IQR=0.00) days at the 12-month assessment (p<0.0001). Likewise, a significant reduction was observed in the Autoinflammatory Disease Activity Index during the study period (p<0.0001). A significant corticosteroid sparing effect was observed as early as the first 12 months of treatment both in the number of patients requiring corticosteroids (p=0.025) and in the dosages employed (p<0.0001). A significant reduction was identified in the erythrocyte sedimentation rate (p<0.0001), C-reactive protein (p<0.0001), serum amyloid-A (p<0.0001) and in the 24 hour-proteinuria during follow-up (p=0.001). A relapsing-remitting disease course (OR=0.027, C.I. 0.001-0.841, p=0.040) and the frequency of relapses at the start of biologics (OR=0.363, C.I. 0.301-0.953, p=0.034) were significantly associated with a complete response. No severe adverse events were observed. Conclusions: Treatment with biologic agents is highly effective in controlling clinical and laboratory TRAPS manifestations. Patients with a relapsing-remitting course and a lower frequency of flares at the start of treatment show more likely a complete response to biologic agents.
Lingua originaleEnglish
pagine (da-a)1-15
Numero di pagine15
RivistaFrontiers in Medicine
Volume2021
DOI
Stato di pubblicazionePubblicato - 2021

Keywords

  • Autoinflammation
  • Tumor necrosis factor receptor associated periodic syndrome

Fingerprint

Entra nei temi di ricerca di 'Biotechnological agents for patients with tumor necrosis factor receptor associated periodic syndrome - Therapeutic outcome and predictors of response: real-life data from the AIDA Network'. Insieme formano una fingerprint unica.

Cita questo